Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables

It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologia internationalis Jg. 89; H. 1; S. 61
Hauptverfasser: Altieri, Vincenzo Maria, Castellucci, Roberto, Palumbo, Pietro, Verratti, Vittore, Sut, Michal, Olivieri, Raffaella, Manco, Rossella, Ricciardulli, Stefano, Nicolai, Michele, Criniti, Pasquale, Tenaglia, Raffaele Lanfranco
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland 01.01.2012
Schlagworte:
Adult
Aged
Aged, 80 and over
Chemotherapy, Adjuvant
Chi-Square Distribution
Cystectomy - adverse effects
Disease Progression
Female
Humans
Immunotherapy
Italy
Male
Middle Aged
Multivariate Analysis
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasms, Multiple Primary
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Tumor Burden
Urinary Bladder Neoplasms - immunology
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - surgery
Italy
ISSN:1423-0399, 1423-0399
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer (EORTC) risk tables. Between 2002 and 2011, a total of 259 patients with NMIBC were treated with transurethral resection of bladder cancer. According to the clinical and pathological factors used by the EORTC scoring system, the patients were divided into four groups, and for each group, the probabilities of recurrence and progression were calculated. The recurrence and progression rates of NMIBC of our patients were similar to those in the EORTC risk score system. Moreover, in our sample group, we found a minimally significant reduction in the recurrence rate in the intermediate- and high-risk groups. From the results obtained, we considered it essential to introduce the use of EORTC risk tables into our clinical practice to determine the recurrence and progression of NMIBC.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1423-0399
1423-0399
DOI:10.1159/000336516